UA102541C2 - Сполука 3-амінокарбазолу, фармацевтична композиція, яка її містить, та спосіб її одержання - Google Patents

Сполука 3-амінокарбазолу, фармацевтична композиція, яка її містить, та спосіб її одержання

Info

Publication number
UA102541C2
UA102541C2 UAA201012088A UAA201012088A UA102541C2 UA 102541 C2 UA102541 C2 UA 102541C2 UA A201012088 A UAA201012088 A UA A201012088A UA A201012088 A UAA201012088 A UA A201012088A UA 102541 C2 UA102541 C2 UA 102541C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
composition containing
preparation
method therefor
aminocarbazole compound
Prior art date
Application number
UAA201012088A
Other languages
English (en)
Russian (ru)
Inventor
Марія Алессандра Алісі
Мария Алессандра Алиси
Нікола Каццолла
Никола Каццолла
Ізабелла Колетта
Изабелла Колетта
Патріція Драгоне
Патриция Драгоне
Гвідо Фурлотті
Гвидо Фурлотти
Барбара Гарофало
Анджело Гугліелмотті
Анджело Гуглиелмотти
Джорджина Мангано
Катеріна Мауджері
Катерина Мауджери
Original Assignee
Ацьєнде Кіміке Ріуніте Анджеліні Франческо А.Чі.Р.А.Ф. С.П.А.
Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ацьєнде Кіміке Ріуніте Анджеліні Франческо А.Чі.Р.А.Ф. С.П.А., Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. filed Critical Ацьєнде Кіміке Ріуніте Анджеліні Франческо А.Чі.Р.А.Ф. С.П.А.
Publication of UA102541C2 publication Critical patent/UA102541C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Даний винахід стосується нових бензоїльних похідних 3-амінокарбазолу, фармацевтичної композиції, яка їх містить, способу одержання та застосування таких сполук для виготовлення медикаменту, який є корисним для лікування або профілактики порушень, пов'язаних з продукуванням простагландину Е2 (PGE2), наприклад, запальних процесів, болю, лихоманки, пухлин, хвороби Альцгеймера та атеросклерозу.
UAA201012088A 2008-05-14 2009-11-05 Сполука 3-амінокарбазолу, фармацевтична композиція, яка її містить, та спосіб її одержання UA102541C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08425336A EP2119705A1 (en) 2008-05-14 2008-05-14 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
PCT/EP2009/055652 WO2009138376A1 (en) 2008-05-14 2009-05-11 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor

Publications (1)

Publication Number Publication Date
UA102541C2 true UA102541C2 (uk) 2013-07-25

Family

ID=39808908

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201012088A UA102541C2 (uk) 2008-05-14 2009-11-05 Сполука 3-амінокарбазолу, фармацевтична композиція, яка її містить, та спосіб її одержання

Country Status (21)

Country Link
US (3) US8637682B2 (uk)
EP (2) EP2119705A1 (uk)
JP (1) JP5551684B2 (uk)
KR (1) KR101721170B1 (uk)
CN (1) CN102026973B (uk)
AR (1) AR071788A1 (uk)
AU (1) AU2009248177B2 (uk)
BR (1) BRPI0912348A2 (uk)
CA (1) CA2721706C (uk)
DK (1) DK2282994T3 (uk)
EA (1) EA019068B1 (uk)
ES (1) ES2428226T3 (uk)
GE (1) GEP20125621B (uk)
HK (1) HK1148272A1 (uk)
IL (1) IL208832A (uk)
MX (1) MX2010012445A (uk)
PL (1) PL2282994T3 (uk)
PT (1) PT2282994E (uk)
SI (1) SI2282994T1 (uk)
UA (1) UA102541C2 (uk)
WO (1) WO2009138376A1 (uk)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710430B (zh) * 2015-03-16 2017-06-06 河南省科学院化学研究所有限公司 一种氨基咔唑类化合物的合成方法
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11845723B2 (en) 2019-12-24 2023-12-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
EP4143194A1 (en) 2020-05-01 2023-03-08 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
CN113072552B (zh) * 2021-03-04 2022-11-04 中国人民解放军北部战区总医院 β-咔波啉类GSK3β/DYRK1A双重抑制剂及其制备方法和抗阿尔兹海默病的应用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024522594A (ja) 2021-06-23 2024-06-21 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4245756B1 (en) 2022-03-17 2024-10-09 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6000900A (en) 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
WO2002051806A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DE10125961A1 (de) 2001-05-29 2002-12-12 Boehringer Ingelheim Int Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
ITMI20050909A1 (it) * 2005-05-19 2006-11-20 Acraf Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
ITMI20051523A1 (it) * 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo

Also Published As

Publication number Publication date
AU2009248177B2 (en) 2013-04-18
GEP20125621B (en) 2012-08-27
EP2119705A1 (en) 2009-11-18
CN102026973A (zh) 2011-04-20
EA201071298A1 (ru) 2011-04-29
DK2282994T3 (da) 2013-09-30
KR20110006691A (ko) 2011-01-20
US8637682B2 (en) 2014-01-28
PL2282994T3 (pl) 2013-11-29
JP5551684B2 (ja) 2014-07-16
IL208832A0 (en) 2011-01-31
US20160102056A1 (en) 2016-04-14
BRPI0912348A2 (pt) 2015-10-13
US10005730B2 (en) 2018-06-26
PT2282994E (pt) 2013-09-04
JP2011520829A (ja) 2011-07-21
EP2282994A1 (en) 2011-02-16
US9249097B2 (en) 2016-02-02
CN102026973B (zh) 2013-07-10
MX2010012445A (es) 2010-12-06
IL208832A (en) 2016-07-31
HK1148272A1 (en) 2011-09-02
AR071788A1 (es) 2010-07-14
CA2721706C (en) 2016-06-28
WO2009138376A1 (en) 2009-11-19
EP2282994B1 (en) 2013-07-03
EA019068B1 (ru) 2013-12-30
US20140107174A1 (en) 2014-04-17
US20110060025A1 (en) 2011-03-10
CA2721706A1 (en) 2009-11-19
AU2009248177A1 (en) 2009-11-19
SI2282994T1 (sl) 2013-10-30
KR101721170B1 (ko) 2017-03-29
ES2428226T3 (es) 2013-11-06

Similar Documents

Publication Publication Date Title
UA102541C2 (uk) Сполука 3-амінокарбазолу, фармацевтична композиція, яка її містить, та спосіб її одержання
MX2010002565A (es) Acidos 6-fenilnicotinicos substituidos y su uso.
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
IN2014MN02106A (uk)
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
TW200736213A (en) Dicarboxylic acid derivatives and their use
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
MA34055B1 (fr) Chlorhydrate d'agomelatine hydrate et sa preparation
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
UA103329C2 (uk) Солі сполук-інгібіторів віл
MX2010009147A (es) Derivados de pirrolidinilo y usos de los mismos.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.